Effect of Coenzyme Q10 on Cognitive Dysfunction and Metabolic Conditions
Causal Effect of Coenzyme Q10 Nutrition and Cognitive Dysfunction in the Metabolic Storm (Hyperglycemia and Sarcopenia) and Brain-derived Neurotrophic Factor
This study is testing if taking coenzyme Q10 can help improve thinking skills and blood sugar levels in people with mild cognitive impairment or Alzheimer's disease who also have high blood sugar.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 50 Years to 80 Years |
| Sex | All |
| Sponsor | Chung Shan Medical University Academic / other |
| Locations | 1 site (Taichung) |
| Trial ID | NCT06040905 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of coenzyme Q10 supplementation on cognitive function and metabolic parameters in patients with mild cognitive impairment and Alzheimer's disease who also have hyperglycemia, with or without pre-sarcopenia. Participants will receive either coenzyme Q10 or a placebo in a randomized, double-blind, cross-over design over a 12-week period. The study will assess changes in brain-derived neurotrophic factor (BDNF), glucose levels, and cognitive performance, alongside various health metrics. Blood samples and other health assessments will be collected to evaluate the effects of the intervention.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with mild cognitive impairment or Alzheimer's disease who also have hyperglycemia and may have pre-sarcopenia.
Not a fit: Patients with severe disabilities, cancer, or significant organ diseases, as well as those currently taking coenzyme Q10 supplements, are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve cognitive function and metabolic health in patients with mild cognitive impairment and Alzheimer's disease.
How similar studies have performed: While there is limited research specifically on coenzyme Q10 for these conditions, antioxidant supplementation has shown promise in related studies, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of mild cognitive impairment (MCI). * Clinical diagnosis of Alzheimer's Disease. * MCI and AD patients with hyperglycemia ( Fasting glucose \>=100 mg/dL). * MCI and AD patients with pre-sarcopenia (low calf circumference, low hand grip, or low muscle endurance). * Must be able to swallow tablets. Exclusion Criteria: * Cancer patients. * Severe heart, lung, liver, and kidney diseases. * Severe disability or aphasia. * Malnutrition (body weight changes \> 5% within one month). * Using coenzyme Q10 supplements. * Warfarin therapy.
Where this trial is running
Taichung
- Chung Shan Medical University Hospital — Taichung, Taiwan (Recruiting)
Study contacts
- Study coordinator: Ping-Ting Lin, Ph.D.
- Email: apt810@csmu.edu.tw
- Phone: +886-4-24730022
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.